A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Eligibility criteria
Qualifiers
Have a history of axial-predominant low back pain
Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
Disqualifiers
Have a non-axial origin low back pain
Have had botulinum or steroid injections to the spine within 1 year of screening
Have had trigger point injection to the spine within 6 months of screening
Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days prior to screening
Trial design
Treatments tested in this trial
- Retatrutide
- Placebo
Treatment groups
586 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov